Research programme: cystic fibrosis therapy - Inologic

Drug Profile

Research programme: cystic fibrosis therapy - Inologic

Alternative Names: Cystic fibrosis therapy research programme - Inologic; INO 4995

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inologic
  • Class Inositol phosphates
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis

Highest Development Phases

  • No development reported Cystic fibrosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA
  • 03 Dec 2003 INO 4995 has received orphan drug status for cystic fibrosis in USA
  • 20 Oct 2003 Inologic has selected a lead compound, INO 4995, for clinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top